Wednesday, July 8, 2026

Patent intelligence · US

US 8975246

Bile acid or bile salt fatty acid conjugates

granted A61KA61K31/575A61K47/554A61P
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 9
Applicant portfolio 11
Related coverage 1
Patent details — US 8975246

Quick answer

US 8975246 (Bile acid or bile salt fatty acid conjugates) is held by GALMED RESEARCH AND DEVELOPMENT LTD. Status: granted. Granted Mar 10, 2015. Expires Mar 5, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
9
CPC classes
A61K, A61K31/575, A61K47/554, A61P, A61P3/04, A61P3/10

More from GALMED RESEARCH AND DEVELOPMENT LTD

Related pharmaceutical patents in our USPTO index.

  1. US 12239712

    Combination therapy for the treatment of liver disease

    GALMED RESEARCH AND DEVELOPMENT LTD · Expires Feb 27, 2045

    granted
  2. US 11571431

    Aramchol salts

    GALMED RESEARCH AND DEVELOPMENT LTD · Expires Feb 2, 2043

    granted
  3. US 11197870

    Treatment for hepatic fibrosis

    GALMED RESEARCH AND DEVELOPMENT LTD · Expires Dec 9, 2041

    granted
  4. US 11166964

    Treatment for modulating gut microbiota

    GALMED RESEARCH AND DEVELOPMENT LTD · Expires Nov 4, 2041

    granted
  5. US 10849911

    Low dose compositions of Aramachol salts

    GALMED RESEARCH AND DEVELOPMENT LTD · Expires Nov 26, 2040

    granted
  6. US 8110564

    Bile acid or bile salt fatty acid conjugates

    Galmed International Limited · Expires Feb 2, 2032

    granted
  7. US 7501403

    Bile acid or bile salt fatty acid conjugates

    Galmed International Limited · Expires Mar 5, 2029

    granted

Related coverage

Frequently asked questions

What is US patent 8975246?

US 8975246 (Bile acid or bile salt fatty acid conjugates) is held by GALMED RESEARCH AND DEVELOPMENT LTD. Status: granted. Granted Mar 10, 2015. Expires Mar 5, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8975246?

GALMED RESEARCH AND DEVELOPMENT LTD is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.

When does US 8975246 expire?

Our index shows an expiration date of Mar 5, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.